Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced Gastric Cancer with FGFR Mutation
NCT05997459Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in gastric cancer (GC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
pemigatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05997459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05997459.